Literature DB >> 19446659

Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.

Andreas Mas Marques1, Tobias Mueller, Justus Welke, Stefan Taube, Christoph Sarrazin, Manfred Wiese, Juliane Halangk, Heiko Witt, Golo Ahlenstiel, Ulrich Spengler, Uwe Goebel, Eckart Schott, Viola Weich, Beate Schlosser, Hermann E Wasmuth, Frank Lammert, Thomas Berg, Eckart Schreier.   

Abstract

Low-density lipoprotein receptor (LDLR) is involved in the entry of hepatitis C virus (HCV) in host cells. We investigated whether three single-nucleotide alterations within LDLR might be associated with the course of hepatitis C infection and response to antiviral therapy. We enrolled 651 individuals with chronic HCV infection who had received interferon-based combination therapy, 174 individuals with self-limited HCV infection, and 516 healthy controls. LDLR c.1171G>A, c.1413G>A, and c.*52G>A genotyping was performed by real-time PCR-based assays. HCV genotype 1-infected individuals who were homozygous for 3'UTR c.*52G were at increased risk for virologic non-response to antiviral therapy compared to virologic responders (66.3% vs. 51.0%, p=0.001). Furthermore, compared to healthy controls, self-limited HCV genotype 1 infection was significantly associated with c.1171A (15.1% vs. 6.6%, p=0.006) and negatively associated with c.1413G>A heterozygosity (33.0% vs. 46.1%, p=0.023). The data indicate that LDLR alterations are correlated with response to interferon-based combination therapy and with self-limitation of HCV 1 infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446659     DOI: 10.1016/j.meegid.2009.05.002

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  4 in total

1.  Association of low-density lipoprotein receptor genotypes with hepatitis C viral load.

Authors:  A Caruz; K Neukam; A Rivero-Juárez; R Herrero; L M Real; A Camacho; P Barreiro; P Labarga; A Rivero; J A Pineda
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

2.  Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

Authors:  K Patel; R Jhaveri; J George; G Qiang; C Kenedi; K Brown; C Cates; A Zekry; H L Tillmann; L Elliott; R Kilaru; J Albrecht; A Conrad; J G McHutchison
Journal:  J Viral Hepat       Date:  2011-05       Impact factor: 3.728

3.  Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

Authors:  F A Di Lello; A Caruz; N I Rallon; A Rivero-Juarez; K Neukam; P Barreiro; A Camacho; S García-Rey; A Rivero; V Soriano; C Cifuentes; J Macias; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-29       Impact factor: 3.267

4.  Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.

Authors:  Mazen Naga; Mona Amin; Dina Algendy; Ahmed Elbadry; May Fawzi; Ayman Foda; Serag Esmat; Dina Sabry; Laila Rashed; Samia Gabal; Manal Kamal
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.